Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
133.06
-0.15 (-0.11%)
Aug 10, 2026, 4:00 PM EDT - Market closed

Gilead Sciences Revenue

Gilead Sciences had revenue of $7.80B in the quarter ending June 30, 2026, with 10.18% growth. This brings the company's revenue in the last twelve months to $30.46B, up 5.52% year-over-year. In the year 2025, Gilead Sciences had annual revenue of $29.44B with 2.40% growth.

Revenue (ttm)
$30.46B
Revenue Growth
+5.52%
P/S Ratio
5.42
Revenue / Employee
$1,791,588
Employees
17,000
Market Cap
164.99B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202529.44B689.00M2.40%
Dec 31, 202428.75B1.64B6.04%
Dec 31, 202327.12B-165.00M-0.60%
Dec 31, 202227.28B-24.00M-0.09%
Dec 31, 202127.31B2.62B10.60%
Dec 31, 202024.69B2.24B9.98%
Dec 31, 201922.45B322.00M1.46%
Dec 31, 201822.13B-3.98B-15.24%
Dec 31, 201726.11B-4.28B-14.09%
Dec 31, 201630.39B-2.25B-6.89%
Dec 31, 201532.64B7.75B31.13%
Dec 31, 201424.89B13.69B122.19%
Dec 31, 201311.20B1.50B15.46%
Dec 31, 20129.70B1.32B15.70%
Dec 31, 20118.39B435.97M5.48%
Dec 31, 20107.95B938.04M13.38%
Dec 31, 20097.01B1.68B31.40%
Dec 31, 20085.34B1.11B26.14%
Dec 31, 20074.23B1.20B39.78%
Dec 31, 20063.03B997.74M49.19%
Dec 31, 20052.03B--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Johnson & Johnson97.93B
Merck & Co.66.57B
AbbVie64.39B
Pfizer63.70B
AstraZeneca61.37B
Novartis AG56.69B
Sanofi55.89B
Novo Nordisk50.34B
Revenue Rankings